You're signed outSign in or to get full access.
RTW Investments, LP
RTW Investments, LP is a New York-headquartered SEC-registered investment adviser founded in 2009. The firm specializes in investing in life sciences and biotechnology sectors, with a focus on identifying and supporting innovative companies developing transformational treatments and technologies. As of 2025, RTW employs approximately 67 professionals, nearly half of whom are investment personnel, and manages funds on behalf of institutional investors, endowments, foundations, and high-net-worth individuals.
Investment Strategy
RTW Investments, LP employs a research-driven investment approach concentrated in the life sciences, particularly biotechnology and medical devices. The firm seeks to identify breakthrough innovations in therapeutics and related technologies by leveraging deep scientific and industry expertise. Its investment strategy spans public and private markets, prioritizing companies with the potential for significant clinical and commercial impact. RTW partners actively with portfolio companies to help advance new therapies, with long-term value creation and impact in healthcare at the core of its philosophy.
Latest 13F Filing Activity
RTW Investments, LP filed their most recent 13F report on Jun 30, 2025 disclosing 72 equity positions with a total 13F market value of $7B. The fund increased holdings in Neurocrine Biosciences Inc., Verona Pharma PLC, Insmed Inc. among other positions. RTW Investments, LP reduced exposure to Axsome Therapeutics Inc., Alkermes PLC, Globus Med Inc. among others.
Top Holdings
Equity Positions (72)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
M MDGL | MADRIGAL PHARMACEUTICALS INC | 8.59% | $603.4M | 1,993,687 | $265.29 | $302.64 | -$57.0M |
N NTRA | NATERA INC | 6.24% | $438.2M | 2,593,645 | $42.81 | $168.94 | +$71.4M |
P PTCT | PTC THERAPEUTICS INC | 5.39% | $378.3M | 7,746,415 | $38.51 | $48.84 | -$3.0M |
A ARGX | ARGENX SE | 5.29% | $371.2M | 673,497 | $352.05 | $551.22 | -$27.4M |
P PTGX | PROTAGONIST THERAPEUTICS INC | 4.53% | $318.1M | 5,756,277 | $24.30 | $55.27 | +$41.6M |
Industry Allocation
Investment Team (15)
| Name | Role | Location | |
|---|---|---|---|
 | Partner | New York, NY , United States | |
 | Research Associate | Scarsdale, NY , United States | |
 | Head Trader | New York, NY , United States | |
N Naveen Yalamanchi | Partner | New York, NY , United States | |
R Robert Rapaport | Research Analyst | New York, NY , United States | |
 | Senior Analyst | New York, NY , United States | |
 | Research Analyst | NY , United States | |
J Jeffrey Wang | Research Analyst | New York, NY , United States | |
 | Partner | New York, NY , United States | |
L Lauren Lee | Research Analyst | New York, NY , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more